Low Testosterone or Functional Suppression? A Practical Approach to Assessment and Management
This webinar has been organised by CliniLink and sponsored by Androlabs. It is intended for UK healthcare professionals only. Androlabs has had no input into the content or choice of speakers, except for the promotional symposium, for which Androlabs chose the content and the speaker. Androlabs products will be discussed during this symposium only
See Sponsors below
£0.00
WEBINAR
THIS EVENT IS OPEN TO UK REGISTERED HEALTHCARE PROFESSIONALS ONLY
Location: MS Teams
Event Agenda
| Time | Topic | Speaker |
|---|---|---|
| 19:00 to 19:05 | Welcome and Introduction | CliniLink Team |
| 19:05 to 19:20 | This is a promotional session organised and funded by Androlabs. It is intended for UK healthcare professionals only. Androlabs products will be discussed during this session. | Andrew Terry HCP Partner -AndroLabs |
| 19:20 to 20:20 | Reading the Grey Zone: Low Testosterone in Real World Practice • Functional hypogonadism linked to obesity and type 2 diabetes • The "grey zone": interpreting testosterone levels of 8 to 12 nmol/L • Latest evidence and guidance from the Society for Endocrinology • Was it anabolic steroid use? Recognising and managing suppression | Mr Sherwin Criseno |
| 20:20 to 21:00 | Q&A and Panel Discussion | Mr Sherwin Criseno and CliniLink Team |
Learning Outcomes
By the end of this webinar, attendees will be able to:- Recognise functional hypogonadism and its links with obesity, type 2 diabetes and other underlying health conditions.
- Interpret testosterone results in the 8 to 12 nmol/L "grey zone" and decide when to repeat, investigate or refer.
- Apply the latest evidence and Society for Endocrinology guidance to the assessment and management of low testosterone in primary care.
- Identify features suggesting anabolic steroid use and approach these conversations with confidence.
- Prioritise lifestyle and comorbidity management before considering testosterone replacement where suppression is functional.
Additional Information
- Free webinar for UK healthcare professionals.
- Certificate of attendance issued for full participation.
- Recording and lecture notes available on demand via CliniLink Academy (membership required).
- Suitable for GPs, pharmacists, nurses and wider primary care MDT members.
- Clinical education is independent of pharmaceutical sponsors.
Meet the Speaker
Sherwin Criseno
Sherwin Criseno is a Nurse Consultant in Endocrinology at University Hospitals Birmingham NHS Foundation Trust and an Honorary Associate Clinical Professor at the University of Birmingham. He leads the largest specialist endocrinology nursing team in Europe and has expertise in pituitary and adrenal disorders, andrology, metabolic bone disease, and adult growth hormone deficiency. An NIHR Clinical Doctoral Research Fellow, his research focuses on the effects of growth hormone treatment discontinuation in adults. He is the first nurse appointed to the Board of Directors of the UK Society for Endocrinology and was recently awarded the Nursing Times Nurse Leader of the Year 2026 and the European Society of Endocrinology 2027 Endocrine Nurse Medal.
Event Sponsors
This webinar has been organised by CliniLink and sponsored by Androlabs. It is intended for UK healthcare professionals only. Androlabs has had no input into the content or choice of speakers, except for the promotional symposium, for which Androlabs chose the content and the speaker. Androlabs products will be discussed during this symposium only
